JC-virus seroconversion in multiple sclerosis patients receiving natalizumab

Multiple Sclerosis Journal

Volumn 20, Issue 7, 2014, Pages 822-829

  Outteryck, Olivier ^a   Zéphir, Héléne ^a   Salleron, Julia ^b   Ongagna, Jean Claude ^c   Etxeberria, Ana ^a   Collongues, Nicolas ^c   Lacour, Arnaud ^a   Fleury, Marie Céline ^c   Blanc, Frédéric ^c   Giroux, Marianne ^a   De Seze, Jérôme ^c   Vermersch, Patrick ^a  

^a UNIV LILLE   (France)

^b Faculté de Médecine Pôle Recherché   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

JC virus; Multiple sclerosis; Natalizumab; Progressive multiple leukoencephalopathy; Quantitative results

Indexed keywords

NATALIZUMAB; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; VIRUS ANTIBODY; BETA INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; MITOXANTRONE;

ADULT; ALLERGIC REACTION; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; JC VIRUS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK FACTOR; SEROCONVERSION; SEROLOGY; SEX RATIO; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; FRANCE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PATHOGENICITY; TIME FACTOR; VIROLOGY; ANTIBODY TITER; COHORT ANALYSIS; FRENCHMAN; INFECTION RATE; NONHUMAN; POPULATION RESEARCH; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; VIRUS REACTIVATION;

ADULT; ANTIBODIES, VIRAL; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRANCE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; OPPORTUNISTIC INFECTIONS; RISK FACTORS; SEROCONVERSION; SEROLOGIC TESTS; TIME FACTORS;

EID: 84902182061     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513505353     Document Type: Article

References (17)

1. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880
2. Lee P, Plavina T, Castro A, et al. A second-generation ELISA (STRATIFY JCVTM DxSelectTM) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013; 57: 141-146
3. Harrell FE Jr, Lee KL, Mark DB. Multivariate prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387 (Pubitemid 26072233)
4. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: Application to the Cox regression model. Stat Med 1992; 11: 2093-2109 (Pubitemid 23066842)
5. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012; 78: 1736-1742
6. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61: 35-47
7. Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111: 3439-3441
8. Krumbholz M, Meinl I, Kumpfel T, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71: 1350-1354
9. Zohren F, Toutzaris D, Klarner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008; 111: 3893-3895
10. Monaco MC, Major EO. The link between VLA-4 and JC virus reactivation. Expert Rev Clin Immunol 2012; 8: 63-72
11. Outteryck O, Ongagna JC, Duhamel A, et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol 2012; 259: 2293-2298
12. Bozic C, Richman S, Plavina T, et al. Anti-JCV antibody prevalence in patients with relapsing remitting multiple sclerosis receiving or considering treatment with natalizumab: Baseline results of STRATIFY2. Neurology 2012; 78: S41.002. DOI: 10.1212/ WNL.78.1-MeetingAbstracts.S41.002
13. Viscidi RP, Khanna N, Tan CS, et al. JC Virus antibody and viraemia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Inf Dis 2011; 53: 711-715
14. Warnke C, Ramanujam R, Plavina T, et al. Changes to anti- JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry. [Epub ahead of print 5 March 2013. DOI 10.1136/jnnp-2012-304332]
15. Bozic C, Richman S, Plavina T, et al. Anti-JCV antibody prevalence in MS patients: Baseline results of STRATIFY-1. Ann Neurol 2011; 70: 742-750
16. Warnke C, Dehmel T, Posevitz-Fejfàr A, et al. Anti-JCV antibody prevalence in a German MS cohort. Mult Scler 2012; 18: 1054-1055
17. Olsson T, Achiron A, Alfredsson L, et al. Anti-JCV antibody prevalence in a multi-national multiple sclerosis cohort. Mult Scler [Epub ahead of print 4 March 2013. DOI. 10.1177/1352458513477925].